Norges Bank purchased a new stake in Catalent Inc (NYSE:CTLT) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 1,513,063 shares of the company’s stock, valued at approximately $47,177,000. Norges Bank owned about 1.04% of Catalent as of its most recent SEC filing.
A number of other institutional investors have also recently bought and sold shares of the stock. Quantamental Technologies LLC acquired a new stake in shares of Catalent during the fourth quarter worth about $47,000. Bremer Trust National Association acquired a new stake in shares of Catalent during the fourth quarter worth about $54,000. Enlightenment Research LLC acquired a new stake in shares of Catalent during the fourth quarter worth about $56,000. First Bank & Trust raised its position in shares of Catalent by 13.9% during the fourth quarter. First Bank & Trust now owns 4,600 shares of the company’s stock worth $143,000 after purchasing an additional 563 shares during the period. Finally, Ramsey Quantitative Systems acquired a new stake in shares of Catalent during the fourth quarter worth about $194,000. Institutional investors and hedge funds own 99.81% of the company’s stock.
Catalent stock traded up $1.37 during midday trading on Friday, reaching $45.79. The stock had a trading volume of 938,248 shares, compared to its average volume of 881,929. The firm has a market cap of $6.67 billion, a PE ratio of 28.80, a P/E/G ratio of 2.36 and a beta of 1.70. Catalent Inc has a 1-year low of $29.23 and a 1-year high of $46.43. The company has a debt-to-equity ratio of 1.36, a quick ratio of 1.63 and a current ratio of 2.08.
In other Catalent news, SVP William Downie sold 7,315 shares of the business’s stock in a transaction that occurred on Friday, February 15th. The stock was sold at an average price of $42.00, for a total transaction of $307,230.00. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Aristippos Gennadios sold 3,392 shares of Catalent stock in a transaction that occurred on Thursday, March 21st. The stock was sold at an average price of $42.18, for a total value of $143,074.56. The disclosure for this sale can be found here. Insiders have sold a total of 54,326 shares of company stock worth $2,303,676 in the last ninety days. Insiders own 1.40% of the company’s stock.
CTLT has been the topic of a number of research analyst reports. Morgan Stanley raised their price target on Catalent from $46.00 to $50.00 and gave the stock an “overweight” rating in a research report on Tuesday, April 16th. First Analysis reissued an “outperform” rating and issued a $49.00 target price on shares of Catalent in a research report on Tuesday, March 5th. Zacks Investment Research raised Catalent from a “hold” rating to a “buy” rating and set a $44.00 target price on the stock in a research report on Wednesday, February 6th. TheStreet raised Catalent from a “c” rating to a “b-” rating in a research report on Wednesday, February 6th. Finally, ValuEngine raised Catalent from a “hold” rating to a “buy” rating in a research report on Monday, April 15th. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $49.57.
WARNING: “Norges Bank Buys New Stake in Catalent Inc (NYSE:CTLT)” was originally reported by Baseball Daily News and is the sole property of of Baseball Daily News. If you are reading this article on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark law. The correct version of this article can be read at https://www.baseballdailydigest.com/news/2019/05/04/norges-bank-takes-position-in-catalent-inc-ctlt.html.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
Featured Article: How does a 12b-1 fee affect fund performance?
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.